MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

NCT00591682 · clinicaltrials.gov ↗
PHASE1
Phase
SUSPENDED
Status
27
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Metastatix, Inc.